TNB-928B

TNB-928B is a fully human **bispecific T-cell engager (TCE)** antibody designed for the treatment of cancer, with a primary focus on ovarian cancer. It utilizes a **bivalent binding arm for folate receptor alpha (FRα)** to selectively target tumor cells that overexpress FRα, while a unique anti-CD3 (F2B) binding arm engages and activates T-cells. The bivalent format confers selectivity by enabling high-avidity binding to tumor cells with high FRα density, leading to T-cell mediated cytotoxicity of such cells while sparing normal cells with low FRα expression. TNB-928B preferentially activates effector T-cells over regulatory T-cells, induces minimal cytokine release, and has demonstrated potent anti-tumor activity and favorable pharmacokinetics in preclinical models. Its design aims to overcome the on-target, off-tumor toxicity that has limited other FRα-targeted immunotherapies[1][2][3].

Other names

FRα-CD3 T-cell engager